1. Optimization of a Nanomedicine-Based Silicon Phthalocyanine 4 Photodynamic Therapy (Pc 4-PDT) Strategy for Targeted Treatment of EGFR-Overexpressing Cancers
- Author
-
Alyssa M. Master, Nancy L. Oleinick, Anirban Sen Gupta, and Megan Livingston
- Subjects
Chemotherapy ,Pathology ,medicine.medical_specialty ,Silicon Phthalocyanine 4 ,biology ,business.industry ,medicine.medical_treatment ,food and beverages ,Pharmaceutical Science ,Photodynamic therapy ,Radiation therapy ,Drug Discovery ,Cancer cell ,Cancer research ,biology.protein ,Molecular Medicine ,Medicine ,Nanomedicine ,Photosensitizer ,Epidermal growth factor receptor ,business - Abstract
The current clinical mainstays for cancer treatment, namely, surgical resection, chemotherapy, and radiotherapy, can cause significant trauma, systemic toxicity, and functional/cosmetic debilitation of tissue, especially if repetitive treatment becomes necessary due to tumor recurrence. Hence there is significant clinical interest in alternate treatment strategies like photodynamic therapy (PDT) which can effectively and selectively eradicate tumors and can be safely repeated if needed. We have previously demonstrated that the second-generation photosensitizer Pc 4 (silicon phthalocyanine 4) can be formulated within polymeric micelles, and these micelles can be specifically targeted to EGFR-overexpressing cancer cells using GE11 peptide ligands, to enhance cell-specific Pc 4 delivery and internalization. In the current study, we report on the in vitro optimization of the EGFR-targeting, Pc 4 loading of the micellar nanoformulation, along with optimization of the corresponding photoirradiation conditions t...
- Published
- 2012
- Full Text
- View/download PDF